Leukemia
Conditions
Brief summary
Ongoing laboratory work into the pathology of Leukaemia:
Detailed description
The investigators will test AML samples sent to the diagnostic laboratory from participants with newly diagnosed or relapsed/refractory AML. Samples will be sent from district general hospitals and teaching hospitals. Results will be returned to referring clinicians in the same way investigators currently return results for samples sent for standard tests. The service will be advertised through the Royal Marsden Website with visibility to both participants and HCPs). The investigators will also inform all the clinicians involved in the AML working party (Dr Taussig is a member of the AML working group). In addition we are looking at diagnostic approaches to IDH 1 and 2 mutation identification. An initial comparison of 50 samples by three analysis methods will be conducted. IDH1 and IDH2 variant discovery will first be performed using an established standard in house SOP (SOP: SMD103) for CE-SSCA
Interventions
PROCEDUREBone Marrow Aspirate
Diagnostic Bone Marrow aspirate
Sponsors
Royal Marsden NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
18 & Over Diagnosis of AML Generic Research consent given
Exclusion criteria
Under 18 No generic research consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathology of Leukaemia cells | 15 years | Pathology of Leukaemia cells |
Countries
United Kingdom
Contacts
Primary ContactLeonora Conneely
Outcome results
None listed